19 compounds.
One complete record.
Kinosis tracks every property of your peptide protocol — dose, route, cycle position, vendor, biomarkers, and daily subjective outcomes. The first platform to aggregate real-world peptide adherence and efficacy data at scale.
19 COMPOUNDS
[SEC_01] UNIVERSAL TRACKING
Tracked for every compound, every dose.
Per-dose log
Source & purity
Structured source tracking enables adverse event signal detection across vendors — if a bad batch appears, the signal shows up in the data.
Protocol change log
Every addition, removal, or modification to an active peptide protocol is timestamped. When you add compound B three weeks into a cycle, Kinosis knows — and your efficacy correlation is measured relative to that change date, not some arbitrary calendar anchor.
[SEC_02] TIER 1 — CORE
Highest adoption · Broadest use case
REPAIR & RECOVERY
BPC-157 (Body Protection Compound-157)
Primary goals
Tissue repair · GI healing · Joint recovery · Systemic inflammation reduction
Cycle
Continuous 12+ weeks · No mandatory off period
Common stacks
TB-500 (Wolverine Stack) · KPV (GI focus)
Biomarkers tracked
hs-CRP · Pain score (1–10) · Energy level
Side effects monitored
Injection site inflammation · Herxheimer response (early cycle)
REPAIR & RECOVERY
TB-500 (Thymosin Beta-4)
Primary goals
Musculoskeletal recovery · Flexibility · Inflammation · Injury prevention
Cycle
12–16 week blocks · 4 week off recommended
Common stacks
BPC-157 (standard repair stack)
Biomarkers tracked
hs-CRP · Pain score · Range of motion
Reconstitution
Bacteriostatic water · Refrigerated · 30 days
GH SECRETAGOGUE
CJC-1295
Primary goals
GH/IGF-1 elevation · Sleep quality · Body composition · Recovery
Heavy meals suppress GH pulse — fasted dosing is not optional.
Cycle
8–12 weeks on · 4 weeks off (mandatory — tachyphylaxis)
Common stacks
Always paired with Ipamorelin
Biomarkers tracked
IGF-1 · TSH · Free T3 · Cortisol · Body composition
Side effects monitored
Carpal tunnel · Water retention · Thyroid suppression · BP · Numbness
GH SECRETAGOGUE
Ipamorelin
Primary goals
GH pulse stimulation · Minimal cortisol/prolactin elevation vs. other GH secretagogues
Cycle
8–12 weeks on · 4 weeks off (mandatory)
Common stacks
CJC-1295 (always paired)
Biomarkers tracked
IGF-1 · Cortisol · Prolactin
Side effects monitored
Water retention · Mild joint pain early in cycle
ANTI-AGING / COGNITIVE
GHK-Cu (Copper Peptide)
Primary goals
Collagen production · Skin quality · Anti-aging · Cognitive clarity · Neurovascular function
Cycle
4–6 weeks on · 2 weeks off (receptor desensitization)
Common stacks
Epithalon (regenerative stack) · Semax (cognitive stack)
Biomarkers tracked
Skin quality (subjective) · Cognitive function score · HRV
[SEC_03] TIER 2 — COGNITIVE
Intranasal delivery · Rapid tachyphylaxis · Mandatory cycling
COGNITIVE ENHANCEMENT
Semax (ACTH 4-7 Analog)
Primary goals
Cognitive performance · Focus · Memory · Learning · Stress resilience
Avoid dosing after 3pm — stimulatory effect disrupts sleep.
Cycle
4–6 weeks on · 2 weeks off
Common stacks
Selank (balanced cognitive + mood) · GHK-Cu
Biomarkers tracked
Cognitive score · HRV · Sleep quality
Side effects monitored
Overstimulation · Tolerance headaches · Sleep disruption
COGNITIVE / MOOD
Selank (Tuftsin Analog)
Primary goals
Anxiety reduction · Mood stabilization · Emotional regulation · Sleep quality
Cycle
4–6 weeks on · 2 weeks off
Common stacks
Semax (Semax for performance, Selank for mood)
Biomarkers tracked
Anxiety score (1–10) · Sleep quality · HRV
Side effects monitored
Tolerance · Rebound anxiety on cessation
[SEC_04] TIER 3 — LONGEVITY / MITOCHONDRIAL
Long cycles · Low tolerance risk · Biological aging mechanisms
LONGEVITY / ANTI-AGING
Epithalon
10–20 mg/dose · SC · 6–12+ months
Telomere support · Sleep-wake cycle regulation · Anti-aging
Biomarkers
Sleep quality · HRV · Melatonin · Energy
Common stacks
GHK-Cu · MOTS-c + SS-31
MITOCHONDRIAL HEALTH
SS-31 (Elamipretide)
0.5–2 mg · SC · 1–3x weekly
Mitochondrial efficiency · Energy production · Metabolic optimization
Biomarkers
Energy level · VO₂ max · HRV · Exercise capacity
Common stacks
MOTS-c (mitochondrial stack)
MITOCHONDRIAL / METABOLIC
MOTS-c
1–5 mg · SC · 1–3x weekly
Insulin sensitivity · Fat oxidation · Metabolic optimization · Exercise capacity
Biomarkers
Fasting glucose · Fasting insulin · HbA1c · Body composition · HRV
Common stacks
SS-31 · AOD-9604
[SEC_05] TIER 4 — IMMUNE
T-cell enhancement · Anti-inflammatory · Wound healing
IMMUNE MODULATION
Thymosin Alpha-1
1–1.6 mg · SC · 1–3x weekly
T-cell/NK cell enhancement · Infection resistance · Vaccine response
Biomarkers
Infection frequency log · Energy · Inflammatory markers
ANTI-INFLAMMATORY / GI
KPV (Lys-Pro-Val)
100–500 mcg · SC/Topical · Daily–2x daily
NF-κB inhibition · GI inflammation · Gut barrier integrity
Biomarkers
GI symptom score · hs-CRP · Stool consistency
IMMUNE / WOUND HEALING
LL-37 (Human Cathelicidin)
250–500 mcg · SC/Topical · 2–3x weekly
Antimicrobial defense · Wound healing · Angiogenesis
Biomarkers
Wound healing rate · Infection frequency · hs-CRP
[SEC_06] TIER 5 — FAT LOSS / METABOLIC
Selective lipolysis · Fasted dosing critical
FAT LOSS / METABOLIC
AOD-9604 (GH Fragment 176-191)
Primary goals
Selective fat lipolysis · Metabolic optimization · Less systemic hormone disruption than full GH secretagogues
Cycle
8–12 weeks on · 2–4 weeks off
Common stacks
MOTS-c (metabolic stack) · CJC-1295/Ipamorelin (body composition)
Biomarkers tracked
Body composition · Fasting glucose · Lipid panel
[SEC_07] TIER 6 — NEXT-GENERATION GLP-1 / HORMONAL
Frontier compounds · Highest potency · Broadest metabolic impact
GLP-1 / WEIGHT LOSS
Retatrutide
Primary goals
Weight loss (up to 29% in trials) · Fatty liver · Metabolic health · Triple receptor: GLP-1 + GIP + glucagon
Status
Not FDA approved — late-stage clinical trials. Ongoing protocol, no established off period.
Biomarkers tracked
Body weight · Fasting glucose · HbA1c · ALT/AST · Lipid panel · Waist circumference
Daily check-in
Hunger score · Craving intensity · Nausea · GI comfort
GH SECRETAGOGUE / VISCERAL FAT
Tesamorelin FDA approved for HIV-associated lipodystrophy · widely used off-label
Primary goals
Visceral fat reduction · IGF-1 elevation · Body composition · Metabolic health
Cycle
12–26 weeks · Off period recommended · Reconstitution: 21 days
Biomarkers tracked
IGF-1 · Waist circumference · Body composition · Fasting glucose · HbA1c
Side effects monitored
Fluid retention · Joint pain · Carpal tunnel · Blood glucose elevation
LONGEVITY / MITOCHONDRIAL / NEUROPROTECTION
Humanin
Primary goals
Neuroprotection · Metabolic health · Longevity · Alzheimer's prevention · Mitochondrial function
Discovered inside mitochondrial DNA. Blood Humanin levels correlate strongly with longevity in population studies. Levels drop with age.
Cycle
12+ weeks · Long-term use being explored
Common stacks
SS-31 + MOTS-c (mitochondrial longevity) · Epithalon
Biomarkers tracked
Cognitive score · Energy · HRV · Fasting insulin · IGF-1
BRAIN / APPETITE / EMOTIONAL HEALTH
Oxytocin FDA approved for obstetric use · intranasal off-label
Primary goals
Emotional eating reduction · Satiety · Social bonding · Stress reduction. Works via satisfaction/fullness signal — different mechanism to GLP-1.
Cycle
Continuous or as needed · No established cycle
Common stacks
Selank (stress + emotional eating)
Biomarkers tracked
Meal frequency · Caloric intake · Anxiety score · Weight
Side effects monitored
Headache · Nausea · Rebound emotional sensitivity on cessation
BRAIN / LIBIDO / REWARD SYSTEM
PT-141 (Bremelanotide) FDA approved for HSDD
Primary goals
Libido · Sexual function · Brain reward system modulation. Acts on melanocortin receptors in the brain — relevant to longevity users tracking hormonal health and quality of life markers.
Dosing
As needed · Max 1x per 24h · 45 min before activity
Common stacks
GHK-Cu (skin/systemic) · Selank (mood support)
Biomarkers tracked
Libido score (subjective) · Mood · Energy
Side effects monitored
Nausea · Flushing · Transient BP increase · Hyperpigmentation with repeated use
[SEC_08] AGGREGATED EFFICACY
The first structured peptide evidence base.
Thousands of people are running peptide protocols right now with no aggregated outcome data to reference. PeptIQ and PeptideJournal exist but are basic loggers — no biomarker integration, no correlation engine, no aggregate layer.
Because every Kinosis peptide protocol is structured — defined compounds, tracked doses, measured biomarkers — the platform can aggregate across users running similar protocols and publish what the data actually shows. Not anecdotes. Anonymized, aggregated, real-world outcome data.
Per-peptide efficacy report includes
- Number of users tracking (anonymized count)
- Average adherence rate and most common dose
- Biomarker trends at 4, 8, and 12 weeks
- Subjective outcome trends (pain, energy, focus)
- Reported side effect frequency
- Most common transition protocols after cycling off
Minimum threshold: 50 users with ≥4 weeks of data before a peptide appears in public reports.
GET STARTED
Track your peptide protocol.
Log via conversation — "I took 300mcg BPC-157 this morning, subcutaneous." Kinosis extracts the compound, dose, route, and time automatically.
Pro free for life · First 1,000 founding members · No credit card needed